|L-R: David Brindley, Jim O'Neil, Michael West, Neil Littman, Bernard Siegel|
Translational medicine is now a focus at CIRM, with a goal to develop and deliver cures and therapies to patients. Now have 10 in clinical trials, and 90 translational programs. Now working at the high school students to foster interest in science/biotech careers.
Jim O'Neil is a partner at Mithril Capital Management, which invests in transformative and durable technologies. With a background in as a Regulator at DHHS, he quickly realized that too much regulation is counterproductive. Jim talks about Breakout Labs, which funds emerging technology start ups. He states Mithril wants to right "backwards industries," those which desperately need to be examined and changed to become more efficient. One example he uses is health care, which I can certainly attest to, having worked and consulted in the field for over 20 years.
Lastly, Bernard Siegel, Executive Director of Genetics Policy Institute, talks to us about the underpinning of the field of stem cells, and states the way for the general public to embrace this technology is if we frame what we are doing in a way the public understands and appreciates. For example, one can read the sports page, and learn about the use of stem cells in athletes. The more mainstream the topic of eradicating disease and extending health becomes, we anticipate enhanced acceptance by the general public.